Fate Therapeutics, Inc. (FATE)
0.9184
-0.09
(-9.07%)
USD |
NASDAQ |
Nov 20, 16:00
0.965
+0.05
(+5.07%)
After-Hours: 19:45
Fate Therapeutics Gross Profit (TTM) : -6.689M for Sept. 30, 2026
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | -6.689M |
| June 30, 2026 | -5.497M |
| March 31, 2026 | -6.17M |
| December 31, 2025 | -6.255M |
| September 30, 2025 | -7.514M |
| June 30, 2025 | -7.561M |
| March 31, 2025 | -4.139M |
| December 31, 2024 | -5.331M |
| September 30, 2024 | -5.587M |
| June 30, 2024 | -6.85M |
| March 31, 2024 | -12.43M |
| December 31, 2023 | 45.25M |
| September 30, 2023 | 87.97M |
| June 30, 2023 | 102.56M |
| March 31, 2023 | 121.68M |
| December 31, 2022 | 66.89M |
| September 30, 2022 | 42.24M |
| June 30, 2022 | 30.45M |
| March 31, 2022 | 14.86M |
| December 31, 2021 | 14.86M |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | -0.128M |
| September 30, 2015 | -0.253M |
| June 30, 2015 | -0.368M |
| March 31, 2015 | -0.501M |
| December 31, 2014 | -0.496M |
| September 30, 2014 | -0.50M |
| June 30, 2014 | -0.385M |
Gross Profit Definition
Annual, Interim and Preliminary Items - Commercial, Other Financial Companies
Gross Profit (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit (TTM) Benchmarks
| AVITA Medical, Inc. | 69.75M |
| Agenus, Inc. | 131.74M |
| Amgen, Inc. | 28.84B |
| Anika Therapeutics, Inc. | 78.26M |
| BioCryst Pharmaceuticals, Inc. | 938.98M |